[go: up one dir, main page]

DK4293009T3 - Fenfluraminsammensætninger og fremgangsmåder til fremstilling af samme - Google Patents

Fenfluraminsammensætninger og fremgangsmåder til fremstilling af samme

Info

Publication number
DK4293009T3
DK4293009T3 DK23207021.9T DK23207021T DK4293009T3 DK 4293009 T3 DK4293009 T3 DK 4293009T3 DK 23207021 T DK23207021 T DK 23207021T DK 4293009 T3 DK4293009 T3 DK 4293009T3
Authority
DK
Denmark
Prior art keywords
preparing
methods
same
fenfluramine compositions
fenfluramine
Prior art date
Application number
DK23207021.9T
Other languages
English (en)
Inventor
Derek Londesbrough
Marc W Andersen
Original Assignee
Zogenix International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59065032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4293009(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zogenix International Ltd filed Critical Zogenix International Ltd
Application granted granted Critical
Publication of DK4293009T3 publication Critical patent/DK4293009T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/24—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds
    • C07C209/28—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds by reduction with other reducing agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82—Purification; Separation; Stabilisation; Use of additives
    • C07C209/84—Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives
    • C07C45/80—Separation; Purification; Stabilisation; Use of additives by liquid-liquid treatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/227—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • C07C49/233—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/08—Preparation of carboxylic acids or their salts, halides or anhydrides from nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK23207021.9T 2015-12-22 2016-12-20 Fenfluraminsammensætninger og fremgangsmåder til fremstilling af samme DK4293009T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562271172P 2015-12-22 2015-12-22
EP20210227.3A EP3800177B1 (en) 2015-12-22 2016-12-20 Fenfluramine compositions and methods of preparing the same

Publications (1)

Publication Number Publication Date
DK4293009T3 true DK4293009T3 (da) 2025-08-18

Family

ID=59065032

Family Applications (3)

Application Number Title Priority Date Filing Date
DK23207021.9T DK4293009T3 (da) 2015-12-22 2016-12-20 Fenfluraminsammensætninger og fremgangsmåder til fremstilling af samme
DK16879990.6T DK3393655T3 (da) 2015-12-22 2016-12-20 Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK20210227.3T DK3800177T3 (da) 2015-12-22 2016-12-20 Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK16879990.6T DK3393655T3 (da) 2015-12-22 2016-12-20 Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK20210227.3T DK3800177T3 (da) 2015-12-22 2016-12-20 Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme

Country Status (25)

Country Link
US (4) US10351509B2 (da)
EP (3) EP3800177B1 (da)
JP (3) JP6893213B2 (da)
KR (1) KR102688278B1 (da)
CN (2) CN113499330B (da)
AU (3) AU2016379346B2 (da)
BR (1) BR112018011777A2 (da)
CA (1) CA3007286A1 (da)
DK (3) DK4293009T3 (da)
ES (3) ES3040587T3 (da)
FI (2) FI4293009T3 (da)
HR (3) HRP20250432T1 (da)
HU (3) HUE053114T2 (da)
IL (3) IL286391B (da)
LT (3) LT4293009T (da)
MX (2) MX391077B (da)
PL (3) PL3393655T3 (da)
PT (3) PT3393655T (da)
RS (1) RS61506B1 (da)
RU (2) RU2731179C2 (da)
SA (1) SA518391868B1 (da)
SG (2) SG10202005916QA (da)
SI (3) SI4293009T1 (da)
WO (1) WO2017112702A1 (da)
ZA (1) ZA201803583B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
KR102688278B1 (ko) * 2015-12-22 2024-07-26 조게닉스 인터내셔널 리미티드 펜플루라민 조성물 및 그 제조 방법
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
CA3032996C (en) 2016-08-24 2025-05-06 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US10682317B2 (en) * 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
WO2020112460A1 (en) * 2018-11-30 2020-06-04 Zogenix International Limited A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
EP4031114A1 (en) 2019-09-17 2022-07-27 Zogenix International Limited Methods of treating epileptic patients with fenfluramine
WO2021117057A1 (en) * 2019-12-10 2021-06-17 Maithri Drugs Pvt Ltd Polymorph of n-ethyl-1-(3-(trifluoromethyl)phenyl)propan-2-amine hydrochloride and process for preparation thereof
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023037182A2 (en) * 2021-08-19 2023-03-16 Biophore India Pharmaceuticals Pvt Ltd AN IMPROVED PROCESS FOR THE PREPARATION OF N-ETHYL- α -METHYL-3-(TRIFLUOROMETHYL)PHENETHYLAMINE HYDROCHLORIDE

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR104F (da) * 1960-11-05
US3117160A (en) 1961-07-27 1964-01-07 Pfizer & Co C Aralkylamines
US3198834A (en) * 1964-07-27 1965-08-03 Snc Science Union Et Compagnie Optical isomers of trifluoromethylated phenethylamines
GB1254332A (en) 1969-02-27 1971-11-17 Science Union & Cie Amino acids and their derivatives and processes for preparing them
DE2143204C3 (de) 1971-08-28 1979-09-27 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
DE2150399A1 (de) 1971-10-09 1973-04-12 Hoechst Ag Neue oxime
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
JPS54144347A (en) * 1978-05-02 1979-11-10 Nikken Kagaku Kk 3-(2-fluoro-4-biphenylyl)-2-butanone
US4309445A (en) 1980-06-16 1982-01-05 Massachusetts Institute Of Technology d-Fenfluramine for modifying feeding behavior
US4452815A (en) 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
KR870001541B1 (ko) * 1985-06-14 1987-09-02 미쯔이도야쯔 가가꾸 가부시기 가이샤 에폭시수지 경화용 아미노벤질아민 조성물
US4721823A (en) * 1986-09-19 1988-01-26 Pennzoil Products Company Lubricants comprising novel cyclopentanes, cyclopentadienes, cyclopentenes, and mixtures thereof and methods of manufacture
DE3717434C1 (de) * 1987-05-23 1988-09-15 Degussa Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril
KR890003368A (ko) * 1987-08-06 1989-04-14 원본미기재 특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법
US4857533A (en) 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
HU204497B (en) 1989-10-09 1992-01-28 Chinoin Gyogyszer Es Vegyeszet Process for producing phenfluramine
IT1238686B (it) * 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
FR2684552B1 (fr) 1991-12-06 1995-04-28 Adir Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
AU7513494A (en) 1993-08-06 1995-02-28 Upjohn Company, The 2-aminoindans as selective dopamine d3 ligands
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
DK0762877T3 (da) 1994-06-03 2001-07-16 Thejmde Trust Meta-substituerede arylalkylaminer og terapeutiske og diagnostiske anvendelser deraf
IT1298349B1 (it) * 1996-05-29 2000-01-05 Alfa Chem Ital Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina
IT1292885B1 (it) * 1997-04-28 1999-02-11 Alfa Chem Ital Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina.
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US20020098175A1 (en) 1998-06-16 2002-07-25 Zohoungbogbo Mathias C. Dietetic food composition and dietetic method using such composition
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
JP4374441B2 (ja) 1998-12-23 2009-12-02 ジェイピーアイ コマーシャル，リミティド ライアビリティ カンパニー 睡眠発作治療のための、ガンマ−ヒドロキシ酪酸塩の微生物的に安全で安定な液剤
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7124031B1 (en) 2000-05-11 2006-10-17 Medco Health Solutions, Inc. System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
WO2002006826A1 (en) 2000-07-17 2002-01-24 Opt-E-Scrip, Inc. Single-patient drug trials used with accumulated database
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US7585493B2 (en) * 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2003000047A2 (en) 2001-06-22 2003-01-03 Universite Catholique De Louvaine Hydrogel beads or capsules as artificial media for insects oviposition and rearing of endoparasitoids
EP1411955A4 (en) 2001-07-31 2006-07-05 Wyeth Corp SUCRALOSE FORMULATIONS FOR COVERING UNANGEAN TASTE
AUPR732601A0 (en) * 2001-08-28 2001-09-20 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of amines such as ephedrine and inter mediates
RU2317104C2 (ru) * 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
NZ532427A (en) 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US7271266B2 (en) 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
AU2003260282A1 (en) * 2002-09-05 2004-03-29 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
WO2005004865A1 (en) 2003-07-08 2005-01-20 Georg-August-Universität Göttingen Use of 5-ht4(a)-serotonin receptor agonists
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
US20050260610A1 (en) 2004-05-20 2005-11-24 Kurtz Richard E Method for diagnosing and prescribing a regimen of therapy for human health risk
KR20080072105A (ko) * 2004-08-26 2008-08-05 화이자 인코포레이티드 단백질 티로신 키나제 저해제 중간체의 제조를 위한거울상이성질선택적 생물학적 전환
US9820658B2 (en) 2006-06-30 2017-11-21 Bao Q. Tran Systems and methods for providing interoperability among healthcare devices
CN100567252C (zh) * 2004-10-11 2009-12-09 俞锋 盐酸芬氟拉明原料药和片剂及其制备方法
AU2006225980A1 (en) 2005-03-21 2006-09-28 Health-Smart Limited System for continuous blood pressure monitoring
JP2008542237A (ja) 2005-05-25 2008-11-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トピラメートの小児科用製剤
NZ564892A (en) 2005-06-16 2011-10-28 Bionomics Ltd Methods of treatment, and diagnosis of epilepsy by detecting a D674G mutation in the SCN1A gene
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
US9125900B2 (en) 2005-09-14 2015-09-08 University Of The Witwatersrand, Johannesburg Pharmaceutical composition
EP1926427A4 (en) 2005-09-19 2012-06-06 Biolert Ltd DEVICE AND METHOD FOR DETECTING AN EPILEPTIC EVENT
CA2911569C (en) 2005-11-29 2019-11-26 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007079181A2 (en) 2005-12-28 2007-07-12 Neurovista Corporation Methods and systems for recommending an action to a patient for managing epilepsy and other neurological disorders
KR20080091473A (ko) 2006-02-06 2008-10-13 노파르티스 아게 유기 화합물들의 조합물
EP2041065A2 (en) * 2006-06-08 2009-04-01 Medichem, S.A. Processes for preparing cinacalcet hydrochloride and polymorphic forms thereof
DE102006030113B4 (de) 2006-06-28 2009-02-12 Chemische Fabrik Budenheim Kg Graphitfreier Hochtemperatur-Schmierstoff
EP2061471A4 (en) 2006-08-31 2012-02-01 Univ Alberta PROCESS FOR INHIBITING RESTRICTED DEPRESSION WITH POSITIVE ALLOSTER AMPA RECEPTOR MODULATORS
WO2008095095A2 (en) 2007-01-31 2008-08-07 Quintiles Transnational Corp. Methods and systems for allocating representatives to sites in clinical trials
WO2008096271A2 (en) 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
JP2010520162A (ja) * 2007-02-28 2010-06-10 スミスクライン ビーチャム コーポレーション ステアロイル−ＣｏＡデサチュラーゼ阻害剤であるチアジアゾール誘導体
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
WO2010020585A1 (en) 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
KR101851120B1 (ko) 2008-09-05 2018-04-23 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
US8664442B2 (en) * 2008-09-09 2014-03-04 Chemtura Corporation Anti-oxidants
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
JP2012505172A (ja) 2008-10-09 2012-03-01 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ パラセタモールを有する液体医薬製剤
US20110230473A1 (en) 2008-10-10 2011-09-22 Gordon Richard K Methods and Compositions for Treating Status Epilepticus and Seizures Causing Status Epilepticus
TWI503101B (zh) 2008-12-15 2015-10-11 Proteus Digital Health Inc 與身體有關的接收器及其方法
US20120065999A1 (en) 2009-03-09 2012-03-15 Celgene Corporation Device for Delivering a Drug to a Patient While Restricting Access to the Drug by Patients for Whom the Drug May Be Contraindicated and Methods for Use Thereof
EP2419400A1 (en) 2009-04-15 2012-02-22 Research Triangle Institute Monoamine reuptake inhibitors
WO2010124137A1 (en) 2009-04-22 2010-10-28 Millennium Pharmacy Systems, Inc. Pharmacy management and administration with bedside real-time medical event data collection
US9453027B2 (en) 2009-07-27 2016-09-27 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
AR079862A1 (es) 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
JP5890328B2 (ja) 2010-03-09 2016-03-22 パーセプティメッド インコーポレイテッドＰｅｒｃｅｐｔｉｍｅｄ， Ｉｎｃ． 薬剤の検証及び供給
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
JP2011221623A (ja) 2010-04-06 2011-11-04 Kakimori Suri 在宅診療支援システム及び方法
AU2011255276B2 (en) 2010-05-21 2016-09-22 Research Triangle Institute Phenylmorpholines and analogues thereof
EP2399513B1 (en) 2010-06-23 2017-01-04 Qatar University Qstp-B System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
EP2598159A4 (en) 2010-07-30 2014-01-08 Merck Sharp & Dohme INHIBITION OF THE CYP3A DRUG MIXTURE EXCHANGE
EP3485878A1 (en) 2010-09-01 2019-05-22 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
CA2814230A1 (en) 2010-10-26 2012-05-03 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
RU103209U1 (ru) 2010-10-29 2011-03-27 Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" Клиническая информационная система
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US8748418B2 (en) * 2011-03-18 2014-06-10 Hoffmann-La Roche Inc. 1,4-oxazepines as BACE1 and/or BACE2 inhibitors
JP5693325B2 (ja) 2011-03-29 2015-04-01 小林クリエイト株式会社 健診結果出力システム及び健診結果出力プログラム
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US20140348966A1 (en) 2011-12-22 2014-11-27 Onesmo B. Balemba Garcinia buchananii baker compounds, compositions and related methods
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US20130218586A1 (en) 2012-02-21 2013-08-22 Frederic J. Huser Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
JP6075973B2 (ja) 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
CA2891342A1 (en) 2012-11-15 2014-05-22 Galleon Pharmaceuticals, Inc. Novel orally bioavailable breathing control modulating compounds, and methods of using same
WO2014106825A2 (en) 2013-01-06 2014-07-10 Jonathan Rabinowitz Methods and devices for identifying improper medical reporting
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103342648A (zh) * 2013-07-22 2013-10-09 北京科莱博医药开发有限责任公司 瑞替加滨中间体的制备方法和瑞替加滨的制备方法
ES2813450T3 (es) 2013-08-19 2021-03-23 Univ California Compuestos y métodos para tratar un trastorno epiléptico
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US20150141415A1 (en) 2013-11-20 2015-05-21 Omonike Arike Olaleye Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases
CN103886415A (zh) 2014-03-25 2014-06-25 北京蝶禾谊安信息技术有限公司 药品管理方法和装置
WO2015187988A1 (en) * 2014-06-04 2015-12-10 Intellimedix Composition and methods of treating epilepsy and/or epilepsy-related disorders
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
KR102245345B1 (ko) 2014-09-29 2021-04-28 조게닉스 인터내셔널 리미티드 의약품 배포 제어를 위한 제어 시스템
CN115487313A (zh) 2015-02-06 2022-12-20 马瑞纳斯制药公司 静脉内加奈索酮制剂及其用途
JP6884703B2 (ja) 2015-02-25 2021-06-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 障害を治療するための５ｈｔ作動薬
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
JP6668045B2 (ja) 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
LT3310362T (lt) 2015-06-17 2019-11-11 Univ Columbia Deoksinukleozidų terapija, skirta ligoms, sukeltoms nesubalansuotų nukleotidų telkinių, įskaitant mitochondrijų dnr išeikvojimo sindromą
KR102207539B1 (ko) 2015-06-30 2021-01-26 네우라드 리미티드 신규한 호흡 제어 조절 화합물, 및 그의 제조 및 사용 방법
US10004749B2 (en) 2015-07-22 2018-06-26 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
PT3340971T (pt) 2015-08-24 2024-06-05 Zogenix International Ltd Métodos de tratamento da síndrome de lennox-gastaut com utilização de fenfluramina
US20220193082A1 (en) 2015-09-14 2022-06-23 Zogenix International Limited Combination treatment of specific forms of epilepsy
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
EP3170807B1 (en) 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
KR102688278B1 (ko) * 2015-12-22 2024-07-26 조게닉스 인터내셔널 리미티드 펜플루라민 조성물 및 그 제조 방법
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
JP6753418B2 (ja) 2016-01-14 2020-09-09 Ａｇｃ株式会社 フッ素樹脂含有溶液、フッ素樹脂含有溶液の製造方法、塗料組成物および塗装物品
US20190083425A1 (en) 2016-08-24 2019-03-21 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
CA3032996C (en) 2016-08-24 2025-05-06 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
BR112019023483A2 (pt) 2017-05-09 2020-06-30 Zogenix International Limited composição farmacêutica para uso no tratamento, na prevenção e/ou no melhoramento dos sintomas da síndrome de doose, e, kit para tratar, prevenir e/ou melhorar um sintoma da síndrome de doose
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US20190091173A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Method of increasing time between convulsive seizures
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US20190247333A1 (en) 2017-09-26 2019-08-15 Zogenix International Limited Method of reduction in convulsive seizure frequency
US11352882B2 (en) 2018-03-12 2022-06-07 Cameron International Corporation Plug assembly for a mineral extraction system
AU2019255745A1 (en) 2018-04-18 2020-11-19 The Trustees Of Columbia University In The City Of New York Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
EP3820459A1 (en) 2018-07-10 2021-05-19 Zogenix International Limited Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension
JP2021530541A (ja) 2018-07-27 2021-11-11 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. てんかんの治療方法
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
WO2020112460A1 (en) 2018-11-30 2020-06-04 Zogenix International Limited A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
EP3930841A4 (en) 2019-02-25 2022-11-30 Zogenix International Limited A formulation for improving seizure control
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine

Also Published As

Publication number Publication date
AU2016379346B2 (en) 2021-02-18
EP4293009B8 (en) 2025-07-16
RU2020128323A3 (da) 2021-01-29
HRP20250898T1 (hr) 2025-09-26
US20170174613A1 (en) 2017-06-22
JP2022133279A (ja) 2022-09-13
EP4293009B1 (en) 2025-06-11
HUE072609T2 (hu) 2025-11-28
CN113499330A (zh) 2021-10-15
BR112018011777A2 (pt) 2018-12-04
SG10202005916QA (en) 2020-07-29
HUE071191T2 (hu) 2025-08-28
HRP20250432T1 (hr) 2025-06-06
EP3800177A1 (en) 2021-04-07
EP3800177B1 (en) 2025-01-29
EP4293009A2 (en) 2023-12-20
CN108883399A (zh) 2018-11-23
EP3393655A1 (en) 2018-10-31
KR102688278B1 (ko) 2024-07-26
AU2016379346A1 (en) 2018-07-05
PL3800177T3 (pl) 2025-05-19
RU2018121633A (ru) 2020-01-23
PL3393655T3 (pl) 2021-09-20
SA518391868B1 (ar) 2021-09-08
EP4293009A3 (en) 2024-02-21
LT3800177T (lt) 2025-04-10
LT3393655T (lt) 2021-03-25
RU2731179C2 (ru) 2020-08-31
MX381004B (es) 2025-03-12
LT4293009T (lt) 2025-08-11
RU2020128323A (ru) 2020-10-06
CA3007286A1 (en) 2017-06-29
JP2021054831A (ja) 2021-04-08
HUE053114T2 (hu) 2021-06-28
EP3393655A4 (en) 2019-07-24
JP6893213B2 (ja) 2021-06-23
IL281368B (en) 2021-10-31
HRP20210267T1 (hr) 2021-05-14
MX391077B (es) 2025-03-21
KR20180091924A (ko) 2018-08-16
IL286391A (en) 2021-10-31
CN113499330B (zh) 2025-08-05
ES3024232T3 (en) 2025-06-04
JP7412320B2 (ja) 2024-01-12
US20180148403A1 (en) 2018-05-31
US20210147335A1 (en) 2021-05-20
IL281368A (en) 2021-04-29
DK3393655T3 (da) 2021-03-15
ES3040587T3 (en) 2025-11-03
RS61506B1 (sr) 2021-03-31
ES2861774T3 (es) 2021-10-06
WO2017112702A1 (en) 2017-06-29
AU2021202576A1 (en) 2021-05-27
US10351509B2 (en) 2019-07-16
JP2019501173A (ja) 2019-01-17
AU2021201339A1 (en) 2021-03-18
SI4293009T1 (sl) 2025-09-30
IL286391B (en) 2022-08-01
ZA201803583B (en) 2019-03-27
EP3393655B1 (en) 2020-12-09
US10947183B2 (en) 2021-03-16
JP7394919B2 (ja) 2023-12-08
FI4293009T3 (fi) 2025-09-03
US11634377B2 (en) 2023-04-25
RU2018121633A3 (da) 2020-03-20
PT4293009T (pt) 2025-09-08
SG11201804811WA (en) 2018-07-30
CN108883399B (zh) 2021-06-22
US20190284124A1 (en) 2019-09-19
PT3393655T (pt) 2021-02-23
IL259703B (en) 2021-04-29
AU2021202576B2 (en) 2022-03-03
FI3800177T3 (fi) 2025-04-29
AU2021201339B2 (en) 2021-10-21
SI3393655T1 (sl) 2021-05-31
IL259703A (en) 2018-07-31
PL4293009T3 (pl) 2025-10-06
PT3800177T (pt) 2025-05-02
MX2021000482A (es) 2022-03-29
SI3800177T1 (sl) 2025-06-30
US10351510B2 (en) 2019-07-16
DK3800177T3 (da) 2025-03-31

Similar Documents

Publication Publication Date Title
DK4293009T3 (da) Fenfluraminsammensætninger og fremgangsmåder til fremstilling af samme
DK3676297T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
DK3386534T3 (da) Sammensætninger og fremgangsmåder til internalisering af enzymer
KR20180084891A (ko) 구조 조성물 및 방법
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3316909T5 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3134130T3 (da) Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK2924093T3 (da) Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
DK3294700T3 (da) Fremgangsmåde til fremstilling af limonen-4-ol
DK3283136T4 (da) Hydrofile belægninger og fremgangsmåder til dannelse af samme
EP3339331A4 (en) COMPOSITION
EP3398996A4 (en) COMPOSITION
DK3408326T3 (da) Elastomerartikler, sammensætninger og fremgangsmåder til fremstilling deraf
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3394259T3 (da) Sammensætninger og fremgangsmåder til reducering af tau-ekspression
DK3319948T3 (da) Acesulfam-kaliumsammensætninger og fremgangsmåder til fremstilling af disse
GB201500692D0 (en) Curable compositions and membranes
DK3250182T3 (da) Dispergible sammensætninger
DK3334726T3 (da) Plinabulinsammensætninger
DK3322695T3 (da) Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3319949T3 (da) Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse
EP3395887C0 (en) FLUOROR RUBBER COMPOSITION